Vertebral fragility fractures lead to significant morbidity and mortality. They are also important predictors of future vertebral and non-vertebral fractures. Effective evidence based interventions are available to manage both pain and recurrent fracture risk after a vertebral fracture. However, identification of vertebral fractures remains a significant clinical challenge. This talk will highlight the importance of vertebral fractures for the general rheumatologist from an epidemiological, clinical, diagnostic, and therapeutic and health economic perspective. Disclosures: K.J. consultancies; Amgen, Eli Lilly, Shire, Internis, Consilient Health, Stirling Anglia Pharmaceuticals, Mereo Biopharma, Optasia, Kyowa Kirin Hakin, UCB. Shareholder/stock ownership; Zebra Medical Vision. Pain is the most debilitating and persistent symptom of rheumatoid arthritis (RA) that remains after successful suppression of joint inflammation by disease-modifying anti-rheumatic drugs. These clinical observations suggest dissociation between pain and inflammation in RA and we are investigating the possible mechanisms underlying the insurgence and maintenance of pain in pre-clinical models of RA with particular emphasis on neuro-immune interactions. In RA, pain is initially driven by synovial inflammation and sensitisation of sensory neurons innervating the joint (peripheral sensitisation) and then maintained by concomitant neuronal plasticity at the first sensory synapse within the spinal cord (central sensitisation). Neuro-immune interactions contribute significantly to both peripheral and central sensitisation. Specifically, microglia in the spinal cord contribute to sensitisation by the release of pro-inflammatory mediators such as cytokines. Despite the limitations of animal models, the collagen-induced arthritis (CIA) model in rodents has strong similarities with the human disease and mimics the major stages in the development of human inflammatory arthritis and its temporal progression. In the rat CIA model, mechanical allodynia of the hind paw is detected seven days after collagen immunisation, whilst the onset of clinical scores and ankle/paw swelling occurs later on (day 11-14), and inflammation peaks on day 18. From seven days after immunization, lumbar dorsal root ganglia (DRG) nociceptive neurons derived from the ankle joints are activated, and convey noxious signalling to the spinal cord. The consequent increase in afferent barrage is associated with increased microglia and neuronal activity in the dorsal horn. Consistent with a role of microglia in central sensitization, the activation of microglia temporally correlates with allodynia, but not paw swelling. The levels of the cytokine IL-1beta are elevated in cerebrospinal fluid (CSF) at seven days and intrathecal delivery of a P2X7 receptor antagonist (day 1-7) prevents the development of allodynia, the activation of microglia and the surge in IL1beta in the CSF. At later time-points (day 18), the increased afferent barrage into the dorsal horn of the spinal cord becomes even more pronounced. This augmented primary afferent input is biologically relevant as inhibitors of neuronal and microglial activity, delivered intrathecally from day 11 to 18, attenuated behavioural allodynia. These data suggest a pivotal role of microglial pathway in the mechanisms underlying joint pain before and after the onset of joint inflammation. This is supported by Arthritis Research UK. Disclosures: M.M. performs consultancy work for Kancera, Sweden. Grants/research support; MRC. Pain in rheumatoid arthritis is initiated and maintained by articular pathology. It is also dependent on sensitisation of nociceptive pathways influenced by environmental, societal and genetic factors. In turn, persistent pain results in a series of often deleterious emotional and behavioral responses that play an important role in determining overall outcome. Although published guidelines offer general assistance for managing arthritis pain, the complexity of underlying mechanisms requires that successful therapy is tailored to the individual patient. The presentation will outline an approach to identifying patients with potential worst pain outcomes, often in the face of successful anti-inflammatory therapy, and suggest a pragmatic multi-modal three-component model for managing pain and associated disability. Disclosures: The author has declared no conflicts of interest.
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Nicola Peel This presentation will cover interventions to improve health-related quality of life in people with acute or chronic vertebral fractures including pain relief, physiotherapy, ergonomics and vertebral augmentation. There will be a focus on practical tips for non-physiotherapy healthcare professionals on postural awareness, simple exercises we can teach our patients in clinic, and how to give advice on physical activity. Pain is the most debilitating and persistent symptom of rheumatoid arthritis (RA) that remains after successful suppression of joint inflammation by disease-modifying anti-rheumatic drugs. These clinical observations suggest dissociation between pain and inflammation in RA and we are investigating the possible mechanisms underlying the insurgence and maintenance of pain in pre-clinical models of RA with particular emphasis on neuro-immune interactions. In RA, pain is initially driven by synovial inflammation and sensitisation of sensory neurons innervating the joint (peripheral sensitisation) and then maintained by concomitant neuronal plasticity at the first sensory synapse within the spinal cord (central sensitisation). Neuro-immune interactions contribute significantly to both peripheral and central sensitisation. Specifically, microglia in the spinal cord contribute to sensitisation by the release of pro-inflammatory mediators such as cytokines. Despite the limitations of animal models, the collagen-induced arthritis (CIA) model in rodents has strong similarities with the human disease and mimics the major stages in the development of human inflammatory arthritis and its temporal progression. In the rat CIA model, mechanical allodynia of the hind paw is detected seven days after collagen immunisation, whilst the onset of clinical scores and ankle/paw swelling occurs later on (day 11-14), and inflammation peaks on day 18. From seven days after immunization, lumbar dorsal root ganglia (DRG) nociceptive neurons derived from the ankle joints are activated, and convey noxious signalling to the spinal cord. The consequent increase in afferent barrage is associated with increased microglia and neuronal activity in the dorsal horn. Consistent with a role of microglia in central sensitization, the activation of microglia temporally correlates with allodynia, but not paw swelling. The levels of the cytokine IL-1beta are elevated in cerebrospinal fluid (CSF) at seven days and intrathecal delivery of a P2X7 receptor antagonist (day 1-7) prevents the development of allodynia, the activation of microglia and the surge in IL1beta in the CSF. At later time-points (day 18), the increased afferent barrage into the dorsal horn of the spinal cord becomes even more pronounced. This augmented primary afferent input is biologically relevant as inhibitors of neuronal and microglial activity, delivered intrathecally from day 11 to 18, attenuated behavioural allodynia. These data suggest a pivotal role of microglial pathway in the mechanisms underlying joint pain before and after the onset of joint inflammation. This is supported by Arthritis Research UK. Disclosures: M.M. performs consultancy work for Kancera, Sweden. Grants/research support; MRC. Pain in rheumatoid arthritis is initiated and maintained by articular pathology. It is also dependent on sensitisation of nociceptive pathways influenced by environmental, societal and genetic factors. In turn, persistent pain results in a series of often deleterious emotional and behavioral responses that play an important role in determining overall outcome. Although published guidelines offer general assistance for managing arthritis pain, the complexity of underlying mechanisms requires that successful therapy is tailored to the individual patient. The presentation will outline an approach to identifying patients with potential worst pain outcomes, often in the face of successful anti-inflammatory therapy, and suggest a pragmatic multi-modal three-component model for managing pain and associated disability. Disclosures: The author has declared no conflicts of interest. 
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